Arbutus swings to $5.1M Q2 net loss as revenue falls to $1.0M; $230M buyback planned
Arbutus Biopharma reported second-quarter 2026 results showing total revenue of $1.0 million and a net loss of $5.1 million, compared with $10.7 million of revenue and net income of $2.5 million a year earlier. The company received $178.4 million from its Moderna settlement in July and plans to return up to about $230 million to shareholders through share repurchases starting in the third quarter, though the board has not yet approved the form and no assurance is given that repurchases will occur.
Key points
- Q2 2026 total revenue was $1.0 million, versus $10.7 million in Q2 2025, which included $9.6 million of previously deferred revenue recognized on the Qilu partnership conclusion.
- Q2 2026 net loss was $5.1 million, or $0.03 per share, compared with net income of $2.5 million, or $0.01 per share, in Q2 2025.
- On July 8, 2026, the company received $178.4 million as its share of the Moderna noncontingent settlement payment.
- Cash, cash equivalents and marketable securities were $92.6 million as of June 30, 2026.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.